drugset
drugset / Trial / NCT06920836

QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study

NCT06920836 ↗

Phase 2 Completed 270 enrolled Wuhan Createrna Science and Technology Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to Evaluate the Efficacy and Safety of QR052107B 100mg， QR052107B 400mg in Patients with Subacute Cough.

Timeline

Start
2023-06-21
Primary completion
2023-11-22
Completion
2023-12-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator QR052107B Unknown 100 mg —
Comparator QR052107B Unknown 400 mg —

Indications

No indication recorded.